Announcement • Aug 13

Bioxytran Reports Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy Patient Treated with PLICID

Bioxytran reported positive clinical results from the first patient treated with PLICID, an investigational galectin antagonist for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The patient, who had been living with CIDP—a rare neurological disorder characterized by progressive weakness and impaired sensory function due to immune-mediated damage to peripheral nerves—received once-weekly intravenous injections of PLICID. Following treatment, the patient was reported to have regained use of their fingers and the ability to walk several miles, representing an encouraging functional improvement in this individual patient. No adverse side effects were reported throughout the treatment course. PLICID is a complex carbohydrate drug designed through Bioxytran's proprietary Artificial Super Intelligence (ASI)-driven drug design platform, developed with researchers at the University of Minnesota Department of Chemistry. The ASI platform interprets nuclear magnetic resonance (NMR) spectroscopy data to calculate and construct novel carbohydrate structures that precisely target specific galectins implicated in disease pathology. The platform uses NMR spectroscopy data and computational methods to support the design and evaluation of carbohydrate structures targeting specific galectins implicated in disease pathology. Bioxytran has worked with Dr. Kevin Mayo, a recognized expert in biomolecular structure and NMR spectroscopy at the University of Minnesota, on biochemical research relating to polysaccharide and oligosaccharide interactions with biologically relevant targets. Bioxytran's galectin antagonist platform leverages linear complex carbohydrate chemical structures to block galectins—proteins implicated in inflammatory, fibrotic, and malignant diseases. While the Company recognizes that observations from a single patient are not sufficient to establish the safety or efficacy of PLICID, the initial clinical observations are encouraging and support further investigation in a larger, appropriately designed clinical study. The observations are indicative of the transformative potential of ASI-designed galectin-targeting therapeutics. Bioxytran intends to pursue further clinical evaluation of PLICID in a larger patient population to further evaluate PLICID's therapeutic profile. CIDP is a rare, acquired immune-mediated neuropathy affecting the peripheral nervous system. Current standard-of-care treatments include intravenous immunoglobulin, corticosteroids, and plasma exchange. Bioxytran is investigating a galectin-targeting approach with a proposed mechanism of action distinct from existing CIDP therapies. Bioxytran continues to advance its pipeline of galectin antagonist therapies across multiple indications, leveraging its ASI-powered carbohydrate design platform. The Company is a clinical-stage pharmaceutical company developing platform technologies in Glycovirology, hypoxia, and degenerative diseases using carbohydrate drug design.

Bioxytran, Inc. Stock Price

BIXT Share Price Performance

BIXT Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Bioxytran, Inc. Key Details

About BIXT

Recent BIXT News & Updates

Bioxytran Reports Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy Patient Treated with PLICID

Bioxytran, Inc. announced delayed annual 10-K filing

Bioxytran Inc Announces Positive Dose Optimization Results And Advances Toward Phase 3 Registrational Trial For ProLectin-M

Recent updates

Bioxytran, Inc. Competitors

Ananda Pharma

Dermata Therapeutics

SenesTech

Liminatus Pharma